ACM
TARA icon

Asymmetry Capital Management’s Protara Therapeutics TARA Stock Holding History

Asymmetry Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-235
Closed -$18K – 38
2017
Q4 		$18K Buy
+235
New +$18.8K 0.02% 31

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Asymmetry Capital Management's TARA Position: Q1 2018 in Review

Asymmetry Capital Management sold out of Protara Therapeutics (TARA) in Q1 2018, closing a stake of 235 shares — an estimated $18K sold.

Asymmetry Capital Management first reported a position in TARA in Q4 2017 and held it in 1 quarter. The position peaked at $18K in Q4 2017. 30 funds tracked by Wall St. Rank hold TARA as of Q1 2018.

  • Asymmetry Capital Management reported no remaining Protara Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 235 Protara Therapeutics shares in Q1 2018, an estimated $18K.
  • Asymmetry Capital Management first reported a position in Protara Therapeutics in Q4 2017 and held it in 1 quarter.
  • Asymmetry Capital Management's Protara Therapeutics position peaked at $18K in Q4 2017.
  • 30 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2018.

Based on Asymmetry Capital Management's 13F filing for Q1 2018, filed 9 May 2018.